Bridging the Gap: Exploring the Causal Relationship Between Metformin and Tumors

Overview

Journal Front Genet

Date 2024 Jul 4

PMID 38962452

Authors

Zexin Zhang

Wenfeng Wu

Zexia Wu

Yihan He

Xuesong Chang

Shenyuan Deng

Rui Zhou

Yadong Chen

Haibo Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Numerous studies have reported that metformin can reduce the risk of tumor development. However, some of the results of these studies are conflicting, necessitating a more reliable evaluation.

Methods: We conducted a Mendelian randomization phenome-wide association study (MR-PheWAS) of tumors to explore the causal relationship between metformin and tumors. Two cohorts of patients taking metformin were obtained from the UK Biobank. Complete phenotype data of the tumors were obtained from FinnGen_R10. We elucidated the causal relationship using a two-sample Mendelian randomization (MR) analysis. More importantly, we conducted a meta-analysis to ensure relatively unbiased results. In the MR analysis, we used the inverse-variance weighted (IVW) method as the main outcome indicator. Subsequently, two cohorts were integrated for the meta-analysis. Finally, we investigated the mechanisms through mediational MR analysis.

Results: MR analysis revealed that metformin might have a causal relationship with 13 tumor-associated phenotypes in the training cohort. Four phenotypes were validated in the testing cohort. In the training and testing cohorts, metformin exhibited a protective effect against brain meningiomas and malignant neoplasms of the breast (HER-positive), oral cavity, tonsils, and the base of the tongue. Intriguingly, after integrating the results of the two cohorts for the meta-analysis, 12 results were statistically significant. Mediational MR analysis suggested that the effects of metformin on brain meningiomas may be weakened by the presence of the family Oxalobacteraceae.

Conclusion: Metformin exhibits potential preventive and therapeutic effects on four types of tumors: brain meningioma, malignant neoplasms of the breast (HER-positive), oral cavity and tonsils, and the base of the tongue. Large randomized controlled trials are required to confirm these findings.

References

Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

Fu Z, Li S, Han S, Shi C, Zhang Y . Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7(1):93. PMC: 8941077. DOI: 10.1038/s41392-022-00947-7. View

Campagnoli C, Berrino F, Venturelli E, Abba C, Biglia N, Brucato T . Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer. 2013; 13(6):433-8. DOI: 10.1016/j.clbc.2013.08.012. View

Bayraktar S, Hernadez-Aya L, Lei X, Meric-Bernstam F, Litton J, Hsu L . Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2011; 118(5):1202-11. PMC: 3207034. DOI: 10.1002/cncr.26439. View

Marei H, Hasan A, Pozzoli G, Cenciarelli C . Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023; 23(1):64. PMC: 10088229. DOI: 10.1186/s12935-023-02902-0. View

Goodwin P, Chen B, Gelmon K, Whelan T, Ennis M, Lemieux J . Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. 2022; 327(20):1963-1973. PMC: 9131745. DOI: 10.1001/jama.2022.6147. View

Dowling R, Zakikhani M, Fantus I, Pollak M, Sonenberg N . Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-12. DOI: 10.1158/0008-5472.CAN-07-2310. View

Tseng C . Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY). 2016; 8(8):1636-49. PMC: 5032687. DOI: 10.18632/aging.101019. View

Feig D . Avoiding the slippery slope: preventing the development of diabetes in women with a history of gestational diabetes. Diabetes Metab Res Rev. 2012; 28(4):317-20. DOI: 10.1002/dmrr.2276. View

10.

Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

11.

Tseng C . Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int. 2018; 38(11):2018-2027. DOI: 10.1111/liv.13872. View

12.

Tsakiridis T, Pond G, Wright J, Ellis P, Ahmed N, Abdulkarim B . Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021; 7(9):1333-1341. PMC: 8323053. DOI: 10.1001/jamaoncol.2021.2328. View

13.

Chen C, Tsai H, Chuang H, Shiu L, Su L, Chiu T . Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A. Sci Rep. 2017; 7(1):1358. PMC: 5430965. DOI: 10.1038/s41598-017-01353-8. View

14.

Wang Y, Yang T, He Q . Strategies for engineering advanced nanomedicines for gas therapy of cancer. Natl Sci Rev. 2021; 7(9):1485-1512. PMC: 8291122. DOI: 10.1093/nsr/nwaa034. View

15.

Tseng C . Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus. Metabolism. 2018; 85:223-226. DOI: 10.1016/j.metabol.2018.04.009. View

16.

Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A . Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021; 53(2):156-165. PMC: 8515199. DOI: 10.1038/s41588-020-00763-1. View

17.

Korologou-Linden R, Bhatta L, Brumpton B, Howe L, Millard L, Kolaric K . The causes and consequences of Alzheimer's disease: phenome-wide evidence from Mendelian randomization. Nat Commun. 2022; 13(1):4726. PMC: 9372151. DOI: 10.1038/s41467-022-32183-6. View

18.

Seliger C, Meier C, Becker C, Jick S, Proescholdt M, Bogdahn U . Diabetes, use of metformin, and the risk of meningioma. PLoS One. 2017; 12(7):e0181089. PMC: 5510861. DOI: 10.1371/journal.pone.0181089. View

19.

Bowden J, Del Greco M F, Minelli C, Zhao Q, Lawlor D, Sheehan N . Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol. 2018; 48(3):728-742. PMC: 6659376. DOI: 10.1093/ije/dyy258. View

20.

Gutkind J, Molinolo A, Wu X, Wang Z, Nachmanson D, Harismendy O . Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. JCI Insight. 2021; 6(17). PMC: 8492350. DOI: 10.1172/jci.insight.147096. View